Pharmaceutical companies Ipsen and Galderma announce that their collaboration for the promotion and distribution of Dysport, Ipsen’s botulinum toxin type A in aesthetic indications, has been extended. Both companies renewed their collaboration in Brazil and Argentina and extended their partnership to Australia where Galderma has the exclusive promotion and distribution rights for Ipsen’s Dysport in glabellar lines indication.
In those territories, Galderma has a portfolio of products and services in the aesthetic and corrective field, including products such as Restylane, Emervel, and Pliaglis. In Brazil, Dysport sales within aesthetics doubled over the initial agreement period of 2008-2012. Both companies also entered into a co-promotion agreement in South Korea where Galderma and Ipsen will co-promote Dysport and Restylane.
In Brazil (where Ipsen will continue to promote Dysport within the neuromuscular disorder indications) and Argentina, the renewed agreements, which will come into force in January 2013, are for an additional five-year period. In Australia, the five-year exclusive distribution agreement came into force on May 1, 2012 and the co-promotion agreement came into force on Nov. 23, 2012 in South Korea.
Under the terms of the agreement signed with Ipsen in 2009, Ipsen granted Galderma exclusive rights to develop, promote and distribute its botulinum toxin type A product in the European Union and certain territories of the Middle East and Eastern Europe. In Europe, the botulinum toxin type A product, specifically formulated for aesthetic use, is branded under the trademark Azzalure and is approved for use in aesthetic indications (glabellar lines). Galderma is currently marketing Azzalure in 16 countries in Europe.
Dysport, Ipsen’s botulinum toxin type A, is a neuromuscular blocking toxin which acts to block acetylcholine release at motor nerve ends and reduces muscular spasm. It was initially developed for the treatment of movement disorders such as cervical dystonia (a chronic condition in which the neck is twisted or deviated), blepharospasm (involuntary eye closure), hemifacial spasm, and various forms of muscle spasticity, including post-stroke arm spasticity, spasticity of the lower limbs (calf) in adults and children with cerebral palsy.
Dysport was originally launched in the United Kingdom in 1991 and has marketing authorizations in 75 countries. The product is currently referred to as Dysport for medical and aesthetic markets, and as Azzalure in aesthetic indication in EU. In March 2006, Ipsen granted Medicis the rights to develop, distribute and commercialize Ipsen’s botulinum toxin type A product in the United States and Canada for aesthetic use.
Release Date: December 3, 2012